Fulltext

Limited doses of immunotherapy use in advanced non-small cell lung cancer elderly patients with ECOG of 2 and high PDL-1 expression

Wong PY 1 , How SH 2 , Hassan R 3 , Abdul Azih MN 2

Affiliations 

  • 1 Department of Respiratory Medicine Hospital Tengku Ampuan Afzan Kuantan Malaysia
  • 2 Department of Medicine Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia
  • 3 Department of Radiology Kulliyyah of Medicine International Islamic University Malaysia Kuantan Malaysia
Aging Med (Milton), 2021 Dec;4(4):345-349.
PMID: 34964016 DOI: 10.1002/agm2.12179

Abstract

Immunotherapy is an effective treatment in advanced non-small cell lung cancer (NSCLC) patients with high PDL-1 expression. Here, we report three such patients with durable response despite limited doses immunotherapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications